Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q99523

UPID:
SORT_HUMAN

ALTERNATIVE NAMES:
100 kDa NT receptor; Glycoprotein 95; Neurotensin receptor 3

ALTERNATIVE UPACC:
Q99523; B4DWI3; C0JYZ0; Q8IZ49

BACKGROUND:
Sortilin serves as a critical receptor involved in various cellular mechanisms, including protein sorting and clearance. It ensures the transport of proteins from the Golgi apparatus to lysosomes and endosomes, independent of the mannose-6-phosphate receptor. By binding to lysosomal proteins in the Golgi, Sortilin facilitates their transport to acidic prelysosomal compartments for dissociation. It also plays a role in neuronal apoptosis by mediating the endocytosis of proapoptotic precursors, acts as a neurotensin receptor, aids in extracellular matrix mineralization, and is crucial for the formation of GLUT4 storage vesicles, enhancing insulin responsiveness.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Sortilin could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.